298€
INTRODUCTORY OFFER 248€
including VAT 24%
(The offer expires at 30/11/2025)
Order by phone:
+30 216 000 5494
I get tested with Colon AiQ – Preventing colorectal cancer
Prevention of colorectal cancer is crucial.
Now I have the opportunity to monitor my gut health consistently and without any stress.
With Colon AiQ, I can now get tested:
- Quickly
- Easily
- With highly accurate results
With a simple blood draw!
Colon AiQ is the ideal solution:
- For those who postpone a colonoscopy
- For interim screening between colonoscopies, especially for sensitive groups
- For individuals who cannot easily undergo a colonoscopy (e.g., sensitivity to anaesthesia, irritable bowel syndrome, etc.)
Frequenty Asked Questions
Colorectal cancer is the third most common cancer worldwide, after breast and lung cancer, and the second most common cause of cancer deaths. However, when detected at an early stage (I & II), it is treatable in approximately 90% of people.
Colon AiQ offers an alternative for those who avoid colonoscopy, allowing for an initial thorough molecular check for colorectal cancer. Additionally, it provides the opportunity for intermediate screening between colonoscopies for high-risk individuals, reducing the need for frequent invasive tests.
Yes, the Colon AiQ test can detect adenomatous polyps that develop in the walls of the colon and may progress into cancer.
The differences between Colon AiQ and stool self-tests (FIT) are substantial:
• Colon AiQ is an innovative, non-invasive test that uses genetic analysis of blood samples to detect specific DNA changes related to the presence of colorectal cancer. Thanks to advanced technology for analyzing epigenetic biomarkers in liquid biopsy, Colon AiQ achieves higher sensitivity compared to the FIT test, especially in the early stages of cancer, even when precancerous lesions (adenomatous polyps) are present. This contributes to early disease detection, enabling doctors to apply more effective treatments.
• In contrast, the stool self-test (FIT – fecal immunochemical test) is one of the most common screening methods, detecting microscopic traces of blood in stool. However, since it only detects the presence of blood, it may fail to identify cancerous or precancerous lesions that do not cause bleeding, and the presence of blood could be due to other causes. Additionally, its sensitivity appears to be limited to more advanced stages of the disease, raising concerns about its ability to detect cancer at early stages.
The process for ordering the Colon AiQ test is simple:
• Register on the ordering platform here.
• We will send the Colon AiQ test kit to your home via courier.
• If you wish, you can schedule a home blood collection appointment (additional charge).
• Send the prepaid kit via ACS, using the collection code found in the kit.
• The sample reaches our laboratory, and the test results are produced. You will then receive a notification to view your results on the app.
Home blood collection is available in the following regions: Athens, Thessaloniki, Achaia, Ioannina, Heraklion, and Larissa.
If you are not in one of these areas, you can have the blood collected at a nearby laboratory and send the kit with the sample back to us at our expense. The collection code is provided in the kit.
No, a doctor’s prescription is not required to take the Colon AiQ test. However, it is generally recommended to consult with your physician, especially if you receive a positive result.
The Colon AiQ test for colorectal cancer requires 10ml of blood.
The Colon AiQ test does not require any special preparation before blood collection.
The results of the Colon AiQ test are provided 12 working days after the sample is received by IQ Genomix.
To view your results, you will log in with your credentials on the platform where you registered.
Payment can be made via IRIS, bank transfer, credit/debit card, in-store payment, or cash on delivery.
In the case of a negative result, the test should ideally be repeated annually or, if this is not possible, every two years.
In the case of a positive test result, you should consult your doctor, as further investigation will be required.
Yes, Colon AiQ is being used internationally as of 2022, with over 250,000 patient tests. It has received the CE IVD mark from the European Union, certifying that it complies with the IVDD 98/79/EC directive for in vitro diagnostic devices.
In addition, it is legally marketed in the EU and has an E.O.F. notification No.: 2830001019897, 2830001020671.
Colon AiQ is a reliable, non-invasive and approved solution for the detection of colorectal cancer.
The protection of your personal data is important to us.
IQ Genomix, as the Data Controller, collects, stores, and processes your personal information in accordance with applicable laws when you visit our Website or use the ordering Platform for the Colon AiQ molecular test.
For more information about our data protection policy and your rights, please visit the following link: https://iqgenomix.com/privacy-policy/ or contact our Data Protection Officer at dataprotection@iqgenomix.com.
Please contact our Customer Service Team at +216 000 5494.